The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment
An expert physician discusses the potential role of novel agents in the management of idiopathic and progressive pulmonary fibrosis.
- An investigational PDE4 inhibitor has been shown to delay progression of disease at 12 weeks in patients with IPF. Why is this exciting for pulmonologists and for patients with IPF as a whole?
- How do you see these investigational therapies being implemented into future treatment paradigms for patients with IPF/PPF?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Recent Videos
Related Content
